{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:16:13Z","timestamp":1790172973834,"version":"4.1.0"},"reference-count":22,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2024,7,28]]},"DOI":"10.1080\/10428194.2024.2346733","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T13:35:29Z","timestamp":1717594529000},"page":"1314-1324","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":22,"title":["Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial"],"prefix":"10.1080","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-8607","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"first","affiliation":[{"name":"Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulraheem","family":"Yacoub","sequence":"additional","affiliation":[{"name":"Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Hospital, Kansas City, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire N.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Haematology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Universit\u00e0 di Firenze, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[{"name":"Department of Hematology, H\u00f4pital Saint-Louis, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Deeg","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Fazal","sequence":"additional","affiliation":[{"name":"Division of Hematology and Cellular Therapy, Allegheny Health Network, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Foltz","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Mattison","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Oncology, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole B.","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ascension Saint Agnes Cancer Institute, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Parameswaran","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation, and Oncology, Avera Cancer Institute, Sioux Falls, SD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Brown","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-695940"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26050"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24592"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22365"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.01.035"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837"},{"key":"e_1_3_5_8_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for myeloproliferative neoplasms V.1.2023. National Comprehensive Cancer Network Inc.; 2023 [cited 2023 Jul 10]. Available from: NCCN.org."},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.148"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0417-z"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01544-x"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04002-9"},{"key":"e_1_3_5_15_1","unstructured":"Inrebic\u00ae (fedratinib) prescribing information. Bristol Myers Squibb; 2023 [cited 2023 Jul 12]. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_inrebic.pdf"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25777"},{"key":"e_1_3_5_17_1","unstructured":"Inrebic\u00ae (fedratinib) summary of product characteristics. Bristol Myers Squibb; 2021 [cited 2023 Jul 12]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/inrebic-epar-product-information_en.pdf"},{"key":"e_1_3_5_18_1","doi-asserted-by":"crossref","unstructured":"Mascarenhas J Gerds AT Kee A et\u00a0al. Clinical outcomes at 3 and 6 months of fedratinib therapy following prior ruxolitinib failure: real-world assessment of spleen symptoms and hematologic response. In: American Society of Hematology (ASH) Annual Meeting; Atlanta GA; Blood (2021) 138 (Supplement 1): 1980 Conference date: Dec 11\u201314 2021.","DOI":"10.1182\/blood-2021-145573"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.7229"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166407"},{"key":"e_1_3_5_21_1","unstructured":"Zofran\u00ae (ondansetron) prescribing information. GlaxoSmithKline; 2016 [cited 2022 Nov 21]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020103s038 020605s022 020781s022lbl.pdf"},{"key":"e_1_3_5_22_1","unstructured":"Imodium\u00ae (loperamide) package insert. Janssen; 2022 [cited 2022 Nov 21]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/017694s052lbl.pdf"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00392-1"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2024.2346733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T17:00:23Z","timestamp":1724950823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2024.2346733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,7,28]]}},"alternative-id":["10.1080\/10428194.2024.2346733"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2024.2346733","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}